famotidine has been researched along with Anxiety Neuroses in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Excerpt | Relevance | Reference |
---|---|---|
"Sixty-four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8-week treatment." | 9.11 | Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. ( Chiba, T; Nakase, H; Seno, H, 2005) |
"Sixty-four functional dyspepsia patients without Helicobacter pylori infection were randomly assigned to 15 mg/day of mosapride, 40 mg/day of famotidine, or 30 mg/day of tandospirone during an 8-week treatment." | 5.11 | Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. ( Chiba, T; Nakase, H; Seno, H, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Seno, H | 1 |
Nakase, H | 1 |
Chiba, T | 1 |
1 trial available for famotidine and Anxiety Neuroses
Article | Year |
---|---|
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzamides; Drug Therapy, Combination; Dyspepsia; Famotidine | 2005 |